Metody leczenia i perspektywy w terapii atopowego zapalenia skóry

David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Advances in experimental medicine and biology. 2017;1027:21-37. doi:https://doi.org/10.1007/978-3-319-64804-0_3

Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy and Asthma Proceedings. 2019;40(2):84-92. doi:https://doi.org/10.2500/aap.2019.40.4202

Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochemia medica. 2019;29(2):214-227. doi:https://doi.org/10.11613/bm.2019.020501

Tan Q, Yang H, Liu E, Wang H. P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL‑17. Molecular Medicine Reports. 2017;16(6):8863-8867. doi:https://doi.org/10.3892/mmr.2017.7689

Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. International Journal of Molecular Sciences. 2020;21(15):5382. doi:https://doi.org/10.3390/ijms21155382

Mathyer ME, Brettmann EA, Schmidt AD, et al. Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa. Nature Communications. 2021;12(1). doi:https://doi.org/10.1038/s41467-021-22821-w

Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nature Reviews Microbiology. 2018;16(3):143-155. doi:https://doi.org/10.1038/nrmicro.2017.157

Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism. 2015;66(1):8-16. doi:https://doi.org/10.1159/000370220

ISAAC - The International Study of Asthma and Allergies in Childhood. isaac.auckland.ac.nz. Accessed May 21, 2023. https://isaac.auckland.ac.nz/index.html

Woldan-Tambor A, Zawilska J, Farmakodynamiki Z, Medycznego U, Adres Ł. Atopowe Zapalenie Skóry (AZS) -Problem XXI Wieku. Accessed May 21, 2023. https://www.ptfarm.pl/pub/File/Farmacja%20Polska/2009/11-2009/08%20%20AZS.pdf

Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs. 2020;80(11):1041-1052. doi:https://doi.org/10.1007/s40265-020-01335-7

Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. American Family Physician. 2020;101(10):590-598. Accessed May 21, 2023. https://www.aafp.org/pubs/afp/issues/2020/0515/p590.html#afp20200515p590-b14

Kim BE, Leung DYM. Significance of Skin Barrier Dysfunction in Atopic Dermatitis. Allergy, Asthma & Immunology Research. 2018;10(3):207. doi:https://doi.org/10.4168/aair.2018.10.3.207

Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal Barrier Dysfunction in Atopic Dermatitis. Journal of Investigative Dermatology. 2009;129(8):1892-1908. doi:https://doi.org/10.1038/jid.2009.133

Salvati L, Cosmi L, Annunziato F. From Emollients to Biologicals: Targeting Atopic Dermatitis. International Journal of Molecular Sciences. 2021;22(19):10381. doi:https://doi.org/10.3390/ijms221910381

Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. Journal of Allergy and Clinical Immunology. 2014;134(4):818-823. doi:https://doi.org/10.1016/j.jaci.2014.08.005

Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. Journal of the American Academy of Dermatology. 2010;63(4):587-593. doi:https://doi.org/10.1016/j.jaad.2009.11.011

Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal Barrier Dysfunction in Atopic Dermatitis. Journal of Investigative Dermatology. 2009;129(8):1892-1908. doi:https://doi.org/10.1038/jid.2009.133

Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: A practice parameter update 2012. Journal of Allergy and Clinical Immunology. 2013;131(2):295-299.e27. doi:https://doi.org/10.1016/j.jaci.2012.12.672

Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020. Allergology International. 2020;69(3):356-369. doi:https://doi.org/10.1016/j.alit.2020.02.006

Jos J, Nuñez Y, Guyatt G, et al. Atopic dermatitis and inflammatory skin disease Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms Systematic Review and Meta-analysis: Allergen Immunotherapy for Atopic Dermatitis Changes in Patient-Important Outcomes 23 RCTs 1957 Participants 13 Countries Systematic Review Meta-analysis Allergen Immunotherapy (AIT) Eczema Severity Improved SCORAD 40% with AIT vs 26% without Moderate certainty Improved DLQI 56% with AIT vs 39% without Moderate certainty Rates depend on route of AIT AD Quality of Life Adverse Reactions Local Systemic Informs Optimal Care Using GRADE Approach JACI. Clinical Immunology. Published online 2023. doi:https://doi.org/10.1016/j.jaci.2022.09.020

Umar BU, Rahman S, Dutta S, et al. Management of Atopic Dermatitis: The Role of Tacrolimus. Cureus. Published online August 18, 2022. doi:https://doi.org/10.7759/cureus.28130

Wollenberg A, Christen‐Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology. 2020;34(12):2717-2744. doi:https://doi.org/10.1111/jdv.16892

Nowicki R, Trzeciak M, Kaczmarski M, et al. Atopic dermatitis. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society, Polish Society of Allergology, Polish Pediatric Society and Polish Society of Family Medicine. Part I. Prophylaxis, topical treatment and phototherapy. Advances in Dermatology and Allergology. 2020;37(1):1-10. doi:https://doi.org/10.5114/ada.2020.93423

Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. The Journal of Dermatology. 2018;45(8):936-942. doi:https://doi.org/10.1111/1346-8138.14501

Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;71(2):327-349. doi:https://doi.org/10.1016/j.jaad.2014.03.030

Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. International Journal of Molecular Sciences. 2021;22(8). doi:https://doi.org/10.3390/ijms22084130

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Salvati L, Cosmi L, Annunziato F. From Emollients to Biologicals: Targeting Atopic Dermatitis. International Journal of Molecular Sciences. 2021;22(19):10381. doi:https://doi.org/10.3390/ijms221910381

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8(1):91-101. doi:https://doi.org/10.1016/j.jaip.2019.06.044

Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology. 2020;184(3):437-449. doi:https://doi.org/10.1111/bjd.19574

Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and Emerging Systemic Treatments for Atopic Dermatitis. Drugs. 2020;80(11):1041-1052. doi:https://doi.org/10.1007/s40265-020-01335-7

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nature Reviews Drug Discovery. Published online August 20, 2021:1-20. doi:https://doi.org/10.1038/s41573-021-00266-6

Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology. 2020;184(3):437-449. doi:https://doi.org/10.1111/bjd.19574

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

NIAMS. Atopic Dermatitis. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Published November 2022. https://www.niams.nih.gov/health-topics/atopic-dermatitis

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nature Reviews Drug Discovery. Published online August 20, 2021:1-20. doi:https://doi.org/10.1038/s41573-021-00266-6

Klasa B, Cichocka-Jarosz E. Atopic Dermatitis - Current State of Research on Biological Treatment. Journal of mother and child. 2020;24(1):53-66. doi:https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. Accessed May 21, 2023. https://clinicaltrials-gov.translate.goog/ct2/show/NCT02465606?_x_tr_sl=auto&_x_tr_tl=pl&_x_tr_hl=pl

Klasa B, Cichocka-Jarosz E. Atopic Dermatitis - Current State of Research on Biological Treatment. Journal of mother and child. 2020;24(1):53-66. doi:https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Webb GJ, Hirschfield GM, Lane PJL. OX40, OX40L and Autoimmunity: a Comprehensive Review. Clinical Reviews in Allergy & Immunology. 2015;50(3):312-332. doi:https://doi.org/10.1007/s12016-015-8498-3

Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2019;144(2):482-493.e7. doi:https://doi.org/10.1016/j.jaci.2018.11.053

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Klasa B, Cichocka-Jarosz E. Atopic Dermatitis - Current State of Research on Biological Treatment. Journal of mother and child. 2020;24(1):53-66. doi:https://doi.org/10.34763/jmotherandchild.2020241.2003.0000010

Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(3):1053-1065. doi:https://doi.org/10.1016/j.jaip.2020.11.034

Edslev S, Agner T, Andersen P. Skin Microbiome in Atopic Dermatitis. Acta Dermato Venereologica. 2020;100(12):adv00164. doi:https://doi.org/10.2340/00015555-3514

Notay M, Foolad N, Vaughn AR, Sivamani RK. Probiotics, Prebiotics, and Synbiotics for the Treatment and Prevention of Adult Dermatological Diseases. American Journal of Clinical Dermatology. 2017;18(6):721-732. doi:https://doi.org/10.1007/s40257-017-0300-2

Luger T, Amagai M, Dreno B, et al. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. Journal of Dermatological Science. 2021;102(3):142-157. doi:https://doi.org/10.1016/j.jdermsci.2021.04.007

Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology. 2019;143(1):26-35. doi:https://doi.org/10.1016/j.jaci.2018.11.015

Koh LF, Ong RY, Common JE. Skin microbiome of atopic dermatitis. Allergology International. Published online November 2021. doi:https://doi.org/10.1016/j.alit.2021.11.001

Park DH, Kim JW, Park HJ, Hahm DH. Comparative Analysis of the Microbiome across the Gut–Skin Axis in Atopic Dermatitis. International Journal of Molecular Sciences. 2021;22(8). doi:https://doi.org/10.3390/ijms22084228

Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clinical Reviews in Allergy & Immunology. 2021;61(3):324-338. doi:https://doi.org/10.1007/s12016-021-08880-3

Bieber T, Bieber. T O M 1 N R 4 2 0 1 0 • D E R M AT O LO G I A P O DY P LO M I E A L E R G O L O G I A Atopowe zapalenie skóry. Dermatologia po Dyplomie. 2008;358(4):17-30. Accessed May 21, 2023. https://podyplomie.pl/publish/system/articles/pdfarticles/000/014/634/original/17-30.pdf?1481034030

Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergologie select. 2021;5(01):293-304. doi:https://doi.org/10.5414/alx02272e

Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergology International. 2022;71(1):40-46. doi:https://doi.org/10.1016/j.alit.2021.10.004

Shalabi MMK, Garcia B, Coleman K, Siller A, Miller AC, Tyring SK. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications. Skin Therapy Letter. 2022;27(1):4-9. Accessed May 21, 2023. https://pubmed.ncbi.nlm.nih.gov/35081305/

Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results. Microorganisms. 2020;8(11):1743. doi:https://doi.org/10.3390/microorganisms8111743

Han MK, Lazarus SC. 44 - COPD: Clinical Diagnosis and Management. ScienceDirect. Published January 1, 2016. Accessed May 21, 2023. https://www.sciencedirect.com/science/article/abs/pii/B9781455733835000440

Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules. 2022;27(15):4964. doi:https://doi.org/10.3390/molecules27154964

Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clinical Reviews in Allergy & Immunology. 2021;61(3):324-338. doi:https://doi.org/10.1007/s12016-021-08880-3

Fertig B, Baillie G. PDE4-Mediated cAMP Signalling. Journal of Cardiovascular Development and Disease. 2018;5(1):8. doi:https://doi.org/10.3390/jcdd5010008

Kleinman E, Laborada J, Metterle L, Eichenfield LF. What’s New in Topicals for Atopic Dermatitis? American Journal of Clinical Dermatology. 2022;23(5):595-603. doi:https://doi.org/10.1007/s40257-022-00712-0

Williams H, Chalmers J. Prevention of Atopic Dermatitis. Acta Dermato Venereologica. 2020;100(12):adv00166. doi:https://doi.org/10.2340/00015555-3516

Balakirski G, Novak N. Atopic Dermatitis and Pregnancy. The Journal of Allergy and Clinical Immunology. 2022;149(4):1185-1194. doi:https://doi.org/10.1016/j.jaci.2022.01.010

Huang R, Ning H, Shen M, Li J, Zhang J, Chen X. Probiotics for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Cellular and Infection Microbiology. 2017;7. doi:https://doi.org/10.3389/fcimb.2017.00392